跳至主要内容
临床试验/NCT00569101
NCT00569101Unknown2 期

A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
9
试验地点
1
主要终点
Reducing proteinuria

研究概览

简要总结

The purpose of this protocol is to determine whether Tacrolimus and Prednisolone are effective and safe in the treatment of the cyclophosphamide-resistant, refractory diffuse proliferative lupus nephritis

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Biopsy-proven lupus nephritis WHO Class IV , IV+V
  • Previously treated by three times over of i.v. cyclophosphamide or 6 months more duration of immunosuppressive treatments (azathioprine, MMF, cyclophosphamide p.o.) for the lupus nephritis
  • spot urine Protein creatinine raio > 1.0
  • RBC > 5 /HPF on microscopic examination of urine

排除标准

  • previous treatment of cyclosporine A or tacrolimus
  • serum Creatinine lever : over 300 mmol/dl
  • allergy to the macrolide antibiotics
  • other systemic organ damage

研究组 & 干预措施

single

Experimental

single arm study (tacrolimus trial group)

干预措施: tacrolimus (Drug)

结局指标

主要结局

Reducing proteinuria

时间窗: 6 months

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验